Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 4/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 11/20 | 0.45 |
| ▸ | PARP11 | Q9NR21 | 9/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 5/20 | 0.44 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30549705 | 0.81 | PARP10 (0.68) | PARP1PARP10PARP11GSK3BPDPK1 | |
| SCHEMBL16013521 | 0.77 | PARP10 (0.51) | PARP1PARP10PARP11GABRG2GABRB3 | |
| SCHEMBL12495613 | 0.77 | MAPK1 (0.48) | PARP1PARP10PARP11MAPKAPK2GSK3B | |
| SCHEMBL1432009 | 0.77 | PARP10 (0.63) | PARP1PARP10PARP11PDPK1 | |
| SCHEMBL30549931 | 0.76 | PARP10 (0.42) | PARP1PARP10PARP11MAPKAPK2MAPK1 | |
| SCHEMBL12459041 | 0.74 | PARP10 (0.71) | PARP1PARP10PARP11PDPK1 | |
| SCHEMBL25797393 | 0.74 | PARP1 (0.51) | PARP1PARP10PARP11MAPKAPK2GABRG2 | |
| SCHEMBL12090703 | 0.72 | PARP10 (0.56) | PARP1PARP10PARP11GABRG2GABRB3 | |
| SCHEMBL29914510 | 0.70 | PARP10 (0.47) | PARP1PARP10PARP11MAPK1PDPK1 | |
| SCHEMBL31027124 | 0.70 | GPR119 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | BEIGENE SWITZERLAND GMBH (CH) | 2025-05-15 | — | — | US | disclosed |
| EP-4448513-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BeiGene Switzerland GmbH (CH) | 2024-10-23 | — | — | EP | disclosed |
| CN-118401514-A | 3, 4-Dihydroisoquinolin-1 (2H) -one derivatives as STING antagonists and uses thereof | 百济神州有限公司 | 2024-07-26 | — | — | CN | disclosed |
| WO-2023109912-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023109912-A1 | 3, 4-DIHYDROISOQUINOLIN-1 (2H) -ONES DERIVATIVES AS STING ANTAGONISTS AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154107-A1 | 3,4-Dihydroisoquinolin-1(2H)-Ones Derivatives as STING Antagonists and the Use Thereof | STING1, IRF3, MAVS | PARP1 548/4885PARP10 709/4885PARP11 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.